Extending blood cancer remission
An innovative blood cancer treatment regime could extend remission by seven months on average, according to a clinical trial led by the University of Leeds.
Myeloma, a blood cancer that accounts for 1 in 50 new cancer diagnoses in the UK, is usually treated with a transplant of stem cells from a patient’s own bone marrow. Supported by high-dose chemotherapy, transplants can lead to a disease-free period – but myeloma typically comes back throughout patients’ lives.
A clinical trial funded by Stand Up To Cancer, Cancer Research UK and Takeda Oncology has tested a treatment in which myeloma relapse patients underwent a second stem cell transplant from their own bone marrow. To suppress cancerous cells after the transplant, doctors used thalidomide, dexamethasone and ixazomib – targeted cancer drugs that are alternatives to chemotherapy. Ixazomib was then used as a longer-term maintenance drug to suppress myeloma cells.
Using these drugs can also improve patients’ quality of life compared to using chemotherapy or long-term steroid use
The findings of the UK Myeloma Research Alliance Myeloma XII (ACCoRd) trial, which were published in the Lancet Haematology, show this treatment resulted in extended disease-free survival by seven months compared with regular treatment.
Gordon Cook, who led the trial, is Professor of Haematology and Director of the Leeds Cancer Research Centre at the University of Leeds, and Consultant Haematologist at Leeds Teaching Hospitals NHS Trust. Professor Cook said: "Not only did the ACCoRd trial improve patients’ time free from myeloma, it showed that using these drugs can also improve patients’ quality of life compared to using chemotherapy or long-term steroid use. Smarter, kinder treatments are a key part of the work we’re doing at the Leeds Cancer Research Centre.”
Suppressing myeloma cells
Ixazomib targets myeloma cells by stopping the breakdown of damaged or unwanted proteins. The build-up of proteins becomes toxic to myeloma cells, as they produce higher amounts of proteins than non-cancerous cells. Coupled with a stem cell transplant, this means new, healthy cells can grow while myeloma cells are repressed.
Because ixazomib is not a steroid, it can reduce treatment-associated health problems with metabolism and infections.
The researchers say the results of this trial, known as Myeloma XII or ACCoRd, present an alternative treatment option for patients who are well enough to go through a second bone marrow transplant.
Dr Nisharnthi Duggan, Science Engagement Manager at Cancer Research UK, said: “It's great that initial results of the ACCoRd trial show that people who received targeted treatment after their stem cell transplant had more time with their loved ones. We're pleased to fund this study investigating potential new treatment options for people with myeloma through our Stand Up To Cancer campaign. We look forward to hearing further results after the final analysis is complete.”
Professor John Snowden, co-author of the study, and Honorary Consultant Haematologist at Sheffield Teaching Hospitals NHS Foundation Trust and Professor of Haematology at the University of Sheffield, said: “It was very special that Sheffield Teaching Hospitals were able to make a major contribution to the recruitment and completion of this important clinical trial, which confirmed benefits for patients with relapsed myeloma by providing them with significantly improved length of remission. We continue to work closely with the Leeds clinical trials team to improve survival and quality of life in patients with myeloma.”
The trial took place across 79 UK hospitals and was funded by Cancer Research UK and Takeda Oncology. The study drug (ixazomib) was provided by Takeda Oncology, and the study is supported by the UK Myeloma Research Alliance. The trial is managed by the Cancer Research UK Clinical Trials Research Unit Leeds (CRUK CTRU) and sponsored by the University of Leeds. The National Institute of Health and Care Research (NIHR) also supported the study through the NIHR Leeds Biomedical Research Centre.
Further information
Top image: Adobe Stock.
‘Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial’ was published in the Lancet Haematology.
The paper was written by Professor Gordon Cook, DSc (University of Leeds), Dr A John Ashcroft, PhD (Mid-Yorkshire NHS Trust), Ethan Senior, MSc (University of Leeds), Catherine Olivier (University of Leeds), Anna Hockaday (University of Leeds), Dr Jeanine Richards (University of Leeds), Professor Jamie D Cavenagh (Barts Health NHS Trust), Professor John A Snowden (Sheffield Teaching Hospitals NHS Foundation Trust/University of Sheffield), Professor Mark T Drayson (University of Birmingham), Dr Ruth de Tute (Leeds Teaching Hospitals NHS Trust), Lesley Roberts (Leek, UK), Dr Roger G Owen Leeds Teaching Hospitals NHS Trust), Prof Kwee Yong (University College London Hospitals), Mamta Garg (Leicester Royal Infirmary), Dr Kevin Boyd (Royal Marsden Hospital), Dr Hamdi Sati (Singleton Hospital), Sharon Gillson (University of Leeds), Professor Mark Cook (Bristol-Myers Squibb), Professor David A Cairns (University of Leeds), and Dr Christopher Parrish (University of Leeds).
